 Renin-Angiotensin System
"Renin-Angiotensin System" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM.
| Descriptor ID |
D012084
|
| MeSH Number(s) |
G03.495.805 G09.330.190.400.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Renin-Angiotensin System".
Below are MeSH descriptors whose meaning is more specific than "Renin-Angiotensin System".
This graph shows the total number of publications written about "Renin-Angiotensin System" by people in UAMS Profiles by year, and whether "Renin-Angiotensin System" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2021 | 1 | 2 | 3 | | 2020 | 0 | 5 | 5 | | 2019 | 2 | 1 | 3 | | 2018 | 2 | 0 | 2 | | 2017 | 1 | 1 | 2 | | 2016 | 1 | 1 | 2 | | 2015 | 0 | 1 | 1 | | 2014 | 0 | 2 | 2 | | 2013 | 2 | 1 | 3 | | 2012 | 1 | 0 | 1 | | 2011 | 1 | 2 | 3 | | 2010 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2007 | 2 | 2 | 4 | | 2006 | 1 | 0 | 1 | | 2005 | 2 | 1 | 3 | | 2004 | 2 | 1 | 3 | | 2003 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Renin-Angiotensin System" by people in Profiles over the past ten years.
-
Ozkizilcik A, Sysavanh F, Patel S, Tandon I, Balachandran K. Local Renin-Angiotensin System Signaling Mediates Cellular Function of Aortic Valves. Ann Biomed Eng. 2021 Dec; 49(12):3550-3562.
-
Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, Liu J, Harville TO. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS One. 2021; 16(9):e0257016.
-
Najjar RS, Schwartz AM, Wong BJ, Mehta PK, Feresin RG. Berries and Their Polyphenols as a Potential Therapy for Coronary Microvascular Dysfunction: A Mini-Review. Int J Mol Sci. 2021 Mar 25; 22(7).
-
Salah HM, Arthur JM, Mehta JL. Implications of renal ACE2 expression in the age of COVID-19. Eur Heart J. 2020 12 21; 41(48):4589-4591.
-
Barill? F, Bassareo PP, Calcaterra G, Romeo F, Mehta JL. Focus on clinical practice: angiotensin-converting enzyme 2 and corona virus disease 2019: pathophysiology and clinical implications. J Cardiovasc Med (Hagerstown). 2020 09; 21(9):630-633.
-
Salah HM, Calcaterra G, Mehta JL. Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection. J Cardiovasc Pharmacol Ther. 2020 11; 25(6):503-507.
-
Batlle D, Soler MJ, Welling PA, Swaminathan S. Authors' Reply. J Am Soc Nephrol. 2020 08; 31(8):1918-1919.
-
Romeo F, Calcaterra G, Barilla F, Mehta JL. Coronavirus disease 2019 infection and the cardiovascular system. J Cardiovasc Med (Hagerstown). 2020 06; 21(6):403-405.
-
Cert?kov? Ch?bov? V, Kujal P, Vanourkov? Z, ?karoupkov? P, Sadowski J, Kompanowska-Jezierska E, Tesar V, Hammock B, Imig J, Maxov? H, Cervenka L, Vaneckov? I. Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats. Kidney Blood Press Res. 2019; 44(6):1493-1505.
-
Bavineni M, Wassenaar TM, Agnihotri K, Ussery DW, L?scher TF, Mehta JL. Mechanisms linking preterm birth to onset of cardiovascular disease later in adulthood. Eur Heart J. 2019 04 07; 40(14):1107-1112.
-
Fouda AY, Fagan SC, Ergul A. Brain Vasculature and Cognition. Arterioscler Thromb Vasc Biol. 2019 04; 39(4):593-602.
-
Ahmed HA, Ishrat T, Pillai B, Fouda AY, Sayed MA, Eldahshan W, Waller JL, Ergul A, Fagan SC. RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial. J Neuroinflammation. 2018 Aug 13; 15(1):229.
-
Cert?kov? Ch?bov? V, Kujal P, ?karoupkov? P, Varnourkov? Z, Vackov? ?, Huskov? Z, Kikerlov? S, Sadowski J, Kompanowska-Jezierska E, Baranowska I, Hwang SH, Hammock BD, Imig JD, Tesar V, Cervenka L. Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. Kidney Blood Press Res. 2018; 43(2):329-349.
-
Johnson EC, Bardis CN, Jansen LT, Adams JD, Kirkland TW, Kavouras SA. Reduced water intake deteriorates glucose regulation in patients with type 2 diabetes. Nutr Res. 2017 Jul; 43:25-32.
-
Dornhoffer JR, Wei T, Zhang H, Miller E, A Cleves M, Richter GT. The expression of renin-angiotensin-aldosterone axis components in infantile hemangioma tissue and the impact of propranolol treatment. Pediatr Res. 2017 07; 82(1):155-163.
-
J?chov? ?, Kopkan L, Huskov? Z, Dole?elov? ?, Neck?r J, Kujal P, Vernerov? Z, Kramer HJ, Sadowski J, Kompanowska-Jezierska E, Reddy RN, Falck JR, Imig JD, Cervenka L. Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2016 10; 34(10):2008-25.
-
Fouda AY, Artham S, El-Remessy AB, Fagan SC. Renin-angiotensin system as a potential therapeutic target in stroke and retinopathy: experimental and clinical evidence. Clin Sci (Lond). 2016 Feb; 130(4):221-38.
-
Al?nov? P, Huskov? Z, Kopkan L, Sporkov? A, J?chov? ?, Neck?r J, Imig JD, Klevstig M, Kol?r F, Rami Reddy N, Falck JR, Sadowski J, Nishiyama A, Kramer HJ, Melenovsk? V, Cervenkov? L, Kujal P, Vernerov? Z, Cervenka L. Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats. Vascul Pharmacol. 2015 Oct; 73:45-56.
-
Sporkov? A, J?chov? S, Huskov? Z, Kopkan L, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kramer HJ, Cervenka L. Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharmacol Physiol. 2014 Dec; 41(12):1003-13.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|